In8Bio (INAB) Operating Expenses (2020 - 2026)
In8Bio (INAB) posted Operating Expenses of $5.3 million for Q1 2026, up 4.63% sequentially from $5.0 million in Q4 2025, and down 6.96% YoY from $5.7 million in Q1 2025.
In8Bio (INAB) Operating Expenses (2020 - 2026) Analysis & Trends
In8Bio has reported Operating Expenses for 7 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Operating Expenses fell 6.96% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (down 29.68% YoY) and the FY2025 annual result came in at $19.9 million, down 35.24% from the prior year.
- Operating Expenses rose to $5.3 million in Q1 2026 per INAB's latest filing, from $5.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $8.7 million in Q2 2024 and troughed at $4.0 million in Q3 2025.
- A 5-year average of $6.7 million and a median of $7.2 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 160.05% in 2022, then sank 44.2% in 2025.
- Over 5 years, Operating Expenses stood at $7.8 million in 2022, then dropped by 2.56% to $7.6 million in 2023, then decreased by 18.08% to $6.2 million in 2024, then retreated by 19.14% to $5.0 million in 2025, then grew by 4.63% to $5.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.3 million, $5.0 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - | 4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.94 Mn |
| Mar 31, 2026 | 5.27 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 6.22 Mn |
| Sep 30, 2024 | 7.11 Mn |
| Jun 30, 2024 | 8.69 Mn |
| Mar 31, 2024 | 8.65 Mn |
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 7.72 Mn |
| Mar 31, 2023 | 7.86 Mn |
| Dec 31, 2022 | 7.80 Mn |
| Sep 30, 2022 | 7.40 Mn |
| Jun 30, 2022 | 7.18 Mn |
| Mar 31, 2022 | 6.15 Mn |
| Dec 31, 2021 | 5.85 Mn |
| Sep 30, 2021 | 3.39 Mn |